GlassScriptPhysician profile
Jacques Joseph Youssef
NPI 1699963835
$2,841.59
in general payments reported to CMS, 2019-2025
28 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $48.70 · 2021: $415 · 2022: $485 · 2023: $574 · 2024: $637 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.73 |
| Education | $124.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $571.05 | 2022-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $340.92 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $305.72 | 2020-2024 | |
| Travere Therapeutics, INC. | $224.61 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $156.69 | 2021-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $138.21 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $119.54 | 2021-2024 | |
| Amgen INC. | $118.27 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Mallinckrodt Hospital Products INC. | $111.97 | 2020-2023 | Acthar |
| Ardelyx, INC. | $111.57 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $101.49 | 2022-2025 | Arexvy |
| Aurinia Pharma U.S., INC. | $80.56 | 2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $60.67 | 2023-2025 | |
| Lundbeck LLC | $52.28 | 2019 | |
| Calliditas Therapeutics US INC. | $47.96 | 2024-2025 | Tarpeyo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.93 | 2023-2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $43.30 | 2019 | |
| Horizon Therapeutics Plc | $37.77 | 2021-2023 | Krystexxa |
| Apellis Pharmaceuticals, INC. | $26.97 | 2025 | Empaveli |
| Shield Therapeutics INC | $22.37 | 2023 | Accrufer |
| Lilly USA, LLC | $22.21 | 2024 | Jardiance |
| Tactile Systems Technology INC | $17.14 | 2020 | |
| Genentech USA, INC. | $16.70 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.25 | 2019 | |
| Genzyme Corporation | $14.45 | 2023 | |
| Shire North American Group INC | $13.13 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.15 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacques Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.